Novel Use of Probenecid to Alleviate Symptoms of Opioid Withdrawal
Chronic Pain, Drug Dependence of Morphine Type, Symptom, Withdrawal
About this trial
This is an interventional treatment trial for Chronic Pain
Eligibility Criteria
Inclusion Criteria:
- Adults with chronic pain. Age greater than or equal to 18 years on the day of enrolment.
- Subjects are currently taking a daily opioid pain medication and planning to taper the dose.
- Participants complete at least one voluntary opioid dose reduction in the twelve-week study period.
- Glomerular filtration rate (GFR) > 50 mL/min
- Capable of providing informed consent
Exclusion Criteria:
- Allergy to probenecid or related drugs
- History of uric acid renal calculi, if known to be urate calculi. If unknown type, then any history of renal calculi.
- Known G6PD deficiency
- Active gout in any joint
Current use of drugs whose exposure may be prolonged, or risk of toxicity increased when used in combination with probenecid:
- Penicillins, specifically ampicillin, penicillin G sodium, and piperacillin
- Carbapenems, specifically doripenem and meropenem
- Lorazepam, midazolam, nitrazepam
- Ketorolac
- Oseltamivir
- Methotrexate
- Mycophenolate
Current use of drugs which may mask symptoms of withdrawal:
a. Clonidine, lofexidine, tizanidine
Current use of drugs which may diminish the effect of probenecid:
a. High dose salicylates including greater than 325 mg PO daily of acetylsalicylic acid (ASA)
- Pregnancy or breastfeeding
- Any major comorbid medical condition which might impair follow-up or result in a safety risk to the participant
Participation in another clinical trial investigating a drug, medical device, or a medical procedure during the 30 days prior to enrolment.
-
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Active Comparator
Placebo Comparator
Probenecid 500 mg PO BID
Probenecid 1000 mg PO BID
Placebo PO BID
Probenecid 500 mg X 1 PO BID and Placebo X 1 PO BID
Probenecid 500mg X 2 PO BID
Placebo X 2 PO BID